18th Aug 2010 17:06
For immediate release |
18 August 2010 |
Alliance Pharma plc
TR-1: Notification of major interests in shares
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii |
Alliance Pharma plc |
|||
2 Reason for the notification (please tick the appropriate box or boxes): |
||||
An acquisition or disposal of voting rights |
Yes |
|||
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached |
|
|||
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments |
|
|||
An event changing the breakdown of voting rights |
|
|||
Other (please specify): |
|
|
||
3. Full name of person(s) subject to the notification obligation: iii |
Aviva plc & its subsidiaries |
|||
4. Full name of shareholder(s) (if different from 3.):iv |
Registered Holder:
BNY Norwich Union Nominees Limited 1,561,425* Chase (GA Group) Nominees Limited 10,044,858*
CUIM Nominee Limited 2,356,377*
*denotes direct interest
BNP Paribas - London 1,846,572
Chase Nominees Limited 6,154,672
State Street Nominees Limited 2,352,851
|
|||
5. Date of the transaction and date on which the threshold is crossed or reached: v |
17 August 2010 |
|||
6. Date on which issuer notified: |
18 August 2010 |
|||
7. Threshold(s) that is/are crossed or reached: vi, vii |
5% to 6% Change at Direct Interest Level |
|||
8. Notified details: |
|||||||||||
A: Voting rights attached to shares viii, ix |
|||||||||||
Class/type of shares if possible using the ISIN CODE |
Situation previous to the triggering transaction |
Resulting situation after the triggering transaction |
|||||||||
Number of Shares |
Number of Voting Rights |
Number of shares |
Number of voting rights |
% of voting rights x |
|||||||
Direct |
Direct xi |
Indirect xii |
Direct |
Indirect |
|||||||
Ordinary Shares GB0031030819 |
23,816,755 |
23,816,755 |
23,316,755 |
13,962,660 |
10,354,095 |
6.01% |
4.45% |
||||
|
|||||||||||
|
|||||||||||
B: Qualifying Financial Instruments |
|||||||||||
Resulting situation after the triggering transaction |
|||||||||||
Type of financial instrument |
Expiration date xiii |
Exercise/ Conversion Period xiv |
Number of voting rights that may be acquired if the instrument is exercised/ converted. |
% of voting rights |
|||||||
|
|
|
|
|
|||||||
|
|||||||||||
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi |
||||||
Resulting situation after the triggering transaction |
||||||
Type of financial instrument |
Exercise price |
Expiration date xvii |
Exercise/ Conversion period xviii |
Number of voting rights instrument refers to
|
% of voting rights xix, xx
|
|
|
|
|
|
|
Nominal |
Delta |
|
|
|||||
Total (A+B+C) |
||||||
Number of voting rights |
Percentage of voting rights |
|||||
24,316,755 |
10.46% |
9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi |
||
The voting rights are managed and controlled by Aviva Investors Global Services Limited, with the following chain of controlled undertakings:-
Aviva Investors Global Services Limited: ·; Aviva plc (Parent Company) ·; Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc) ·; Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva Group Holdings Limited) ·; Aviva Investors Global Services Limited (wholly owned subsidiary of Aviva Investors Holdings Limited)
|
||
|
||
Proxy Voting: |
||
10. Name of the proxy holder: |
See Section 4 |
|
11. Number of voting rights proxy holder will cease to hold: |
|
|
12. Date on which proxy holder will cease to hold voting rights: |
|
|
|
||
13. Additional information: |
Figures are based on the total number of voting rights of 232,533,373. |
|
14. Contact name: |
Neil Whittaker |
|
15. Contact telephone number: |
01603 684420 |
|
Related Shares:
Alliance PharmaAviva